A new treatment option for patients with HCC
eMediNexus, 11 November 2018
remove_red_eye 891 Views
#Gastroenterology #Internal Medicine #Pathology and Lab Medicine
remove_red_eye 891 Views
#Gastroenterology #Internal Medicine #Pathology and Lab Medicine
The FDA has expanded the indications for pembrolizumab (Keytruda) to include advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib (Nexavar)
To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
